

## Imugene Announces Important Pre-clinical Data for Lead Oncolytic Virus at the American Association for Cancer Research 2021 Annual Meeting

---

**SYDNEY, Australia, 12 April 2021:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today announced City of Hope's, Dr Yanghee Woo MD, Associate Clinical Professor, Department of Surgery and Director, Gastroenterology Minimally Invasive Therapy Program presented on the CF33 oncolytic virus program at the American Association for Cancer Research (AACR) 2021 Annual Meeting.

The abstract presentation was entitled '*Subcutaneous Intratumoral Administration of CF33-hNIS-anti-PD-L1 Eradicates Distant Peritoneal Tumors*'. Dr Woo's team engineered CF33-hNIS-antiPDL1, a unique chimeric orthopoxvirus, which shows robust preclinical activity against many solid tumors and inherent strong anti-cancer activity against pancreatic ductal adenocarcinoma (PDAC). The team investigated CF33-hNIS-antiPDL1 for its ability to track and kill distant peritoneal metastases after local virus administration *in vivo*. They showed that subcutaneous intratumoral (SC.IT) delivery of CF33-hNIS-antiPDL1 decreases peritoneal tumor burden and improves survival in a PDAC mouse model.

The presentation also exquisitely demonstrated that <sup>124</sup>I-based PET/CT imaging can be used to visualize SC and peritoneal tumors treated with Imugene's CF33-hNIS-antiPDL1.

The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally recognised surgeon and scientist at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California. CF33 has been developed in two different constructs: one version of the OV is "armed" with an immune checkpoint inhibitor inserted in the virus, which is known as CHECKVacc; and the other an unarmed construct, known as VAXINIA.

The presentation can be viewed on the Imugene website.

For further information please contact:  
Leslie Chong  
Managing Director and Chief Executive Officer  
T: +61 458 040 433  
E: Leslie.Chong@Imugene.com

Follow us on Twitter [@TeamImugene](#)  
Like us on Facebook [@Imugene](#)  
Connect with us on LinkedIn [@Imugene Limited](#)

### **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*